Top

Published in:

Open Access 01-09-2014 | Research Article

Elevated homocysteine level in first-episode schizophrenia patients—the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse

Authors: Blazej Misiak, Dorota Frydecka, Ryszard Slezak, Patryk Piotrowski, Andrzej Kiejna

Published in: Metabolic Brain Disease | Issue 3/2014

Abstract

Accumulating evidence indicates that elevated homocysteine (Hcy) level occurs in first-episode schizophrenia (FES) patients. We included 56 FES patients and 53 healthy controls (HC). Plasma level of Hcy was significantly higher in FES patients than HC (p = 0.044). In addition, plasma levels of high-density lipoproteins (HDL) and folate were significantly lower in FES than in HC (p < 0.001). Positive family history of schizophrenia was associated with lower plasma HDL (p = 0.041) and vitamin B12 (p = 0.017), as well as higher level of Hcy (p = 0.017). Patients with FES, who abused cannabis, had higher levels of Hcy (p = 0.017), as well as lower levels of vitamin B12 (p = 0.017) and HDL (p = 0.041). Plasma Hcy negatively correlated with duration of untreated psychosis (r = −0.272, p = 0.042). There was a positive correlation between Hcy level and the severity of negative symptoms (r = 0.363, p = 0.006) and general psychopathology (r = 0.349, p = 0.008) assessed using Positive and Negative Syndrome Scale (PANSS). Vitamin B12 level was negatively associated with the severity of negative symptoms (r = −0.406, p = 0.002), while folate level negatively correlated with general psychopathology score (r = −0.365, p = 0.006) in PANSS. These results indicate that the severity of one-carbon metabolism alterations and HDL deficiency might be associated with family history of schizophrenia and cannabis abuse. Lower vitamin B12 and folate along with elevated Hcy may influence the severity of FES psychopathology.

Araujo JR, Goncalves P, Martel F (2009) Effect of cannabinoids upon the uptake of folic acid by BeWo cells. Pharmacology 83(3):170–176. doi:10.1159/000192587 PubMedCrossRef

Ayesa-Arriola R, Perez-Iglesias R, Rodriguez-Sanchez JM, Mata I, Gomez-Ruiz E, Garcia-Unzueta M, Martinez-Garcia O, Tabares-Seisdedos R, Vazquez-Barquero JL, Crespo-Facorro B (2012) Homocysteine and cognition in first-episode psychosis patients. Eur Arch Psychiatry Clin Neurosci 262(7):557–564. doi:10.1007/s00406-012-0302-2 PubMedCrossRef

Bahorik AL, Newhill CE, Queen CC, Eack SM (2013) Under-reporting of drug use among individuals with schizophrenia: prevalence and predictors. Psychol Med 1–9. doi:10.1017/S0033291713000548

Bicikova M, Hampl R, Hill M, Ripova D, Mohr P, Putz Z (2011) Neuro- and immunomodulatory steroids and other biochemical markers in drug-naive schizophrenia patients and the effect of treatment with atypical antipsychotics. Neuroendocrinol Lett 32(2):141–147PubMed

Bouaziz N, Ayedi I, Sidhom O, Kallel A, Rafrafi R, Jomaa R, Melki W, Feki M, Kaabechi N, El Hechmi Z (2010) Plasma homocysteine in schizophrenia: determinants and clinical correlations in Tunisian patients free from antipsychotics. Psychiatry Res 179(1):24–29. doi:10.1016/j.psychres.2010.04.008 PubMedCrossRef

Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS (2012) Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res 11(8):4338–4350. doi:10.1021/pr300459d PubMedCrossRef

Casadio P, Fernandes C, Murray RM, Di Forti M (2011) Cannabis use in young people: the risk for schizophrenia. Neurosci Biobehav Rev 35(8):1779–1787. doi:10.1016/j.neubiorev.2011.04.007 PubMedCrossRef

Chen S, Broqueres-You D, Yang G, Wang Z, Li Y, Wang N, Zhang X, Yang F, Tan Y (2013) Relationship between insulin resistance, dyslipidaemia and positive symptom in Chinese antipsychotic-naive first-episode patients with schizophrenia. Psychiatry Res 210(3):825–829. doi:10.1016/j.psychres.2013.08.056 PubMedCrossRef

Coyle JT, Basu A, Benneyworth M, Balu D, Konopaske G (2012) Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications. Handb Exp Pharmacol 213:267–295. doi:10.1007/978-3-642-25758-2_10 PubMedCrossRef

Davis RE, Midalia ND, Curnow DH (1978) Illegal drugs and nutrition in undergraduate students. Med J Aust 1(11):617–620PubMed

de Bree A, Verschuren WM, Blom HJ, Kromhout D (2001) Lifestyle factors and plasma homocysteine concentrations in a general population sample. Am J Epidemiol 154(2):150–154PubMedCrossRef

Dierkes J, Luley C, Westphal S (2007) Effect of lipid-lowering and anti-hypertensive drugs on plasma homocysteine levels. Vasc Health Risk Manag 3(1):99–108PubMedCentralPubMed

Dietrich-Muszalska A, Malinowska J, Olas B, Glowacki R, Bald E, Wachowicz B, Rabe-Jablonska J (2012) The oxidative stress may be induced by the elevated homocysteine in schizophrenic patients. Neurochem Res 37(5):1057–1062. doi:10.1007/s11064-012-0707-3 PubMedCentralPubMedCrossRef

Dong ZQ, Tian YY, Guan X, Wu J, Gu Y, Hu ZQ, Sun XL (2012) Genetic polymorphism of methylenetetrahydrofolate reductase and risk of aggressive behaviour in schizophrenia. Psychiatry Res 200(2–3):1082. doi:10.1016/j.psychres.2012.07.021 PubMedCrossRef

El-Hadidy MA, Abdeen HM, Abd El-Aziz SM, Al-Harrass M (2013) C677T methylenetetrahydrofolate reductase gene polymorphism in schizophrenia and bipolar disorder. Psychiatr Genet. doi:10.1097/YPG.0000000000000020 PubMed

Ellingrod VL, Miller DD, Taylor SF, Moline J, Holman T, Kerr J (2008) Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophr Res 98(1–3):47–54. doi:10.1016/j.schres.2007.09.030 PubMedCentralPubMedCrossRef

Ellingrod VL, Taylor SF, Dalack G, Grove TB, Bly MJ, Brook RD, Zollner SK, Pop-Busui R (2012) Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: the role of folate pharmacogenetics. J Clin Psychopharmacol 32(2):261–265. doi:10.1097/JCP.0b013e3182485888 PubMedCentralPubMedCrossRef

Eren E, Yegin A, Yilmaz N, Herken H (2010) Serum total homocystein, folate and vitamin B12 levels and their correlation with antipsychotic drug doses in adult male patients with chronic schizophrenia. Clin Lab 56(11–12):513–518PubMed

Fernandez-Egea E, Miller B, Bernardo M, Donner T, Kirkpatrick B (2008) Parental history of type 2 diabetes in patients with nonaffective psychosis. Schizophr Res 98(1–3):302–306. doi:10.1016/j.schres.2007.10.002 PubMedCentralPubMedCrossRef

Fleischhacker WW, Siu CO, Boden R, Pappadopulos E, Karayal ON, Kahn RS (2013) Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial. Int J Neuropsychopharmacol 16(5):987–995. doi:10.1017/S1461145712001241 PubMedCrossRef

Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18(6):499–502PubMed

Fujiki Y, Hirashima Y, Seshimo S, Okamoto T, Sugimoto Y, Matsumoto M, Oka T, Kanouchi H (2012) Homocysteine induced SH-SY5Y apoptosis through activation of NADPH oxidase in U251MG cells. Neurosci Res 72(1):9–15. doi:10.1016/j.neures.2011.09.010 PubMedCrossRef

Garcia-Bueno B, Bioque M, Mac-Dowell KS, Barcones MF, Martinez-Cengotitabengoa M, Pina-Camacho L, Rodriguez-Jimenez R, Saiz PA, Castro C, Lafuente A, Santabarbara J, Gonzalez-Pinto A, Parellada M, Rubio G, Garcia-Portilla MP, Mico JA, Bernardo M, Leza JC (2013) Pro-/anti-inflammatory dysregulation in patients with first episode of psychosis: toward an integrative inflammatory hypothesis of schizophrenia. Schizophr Bull. doi:10.1093/schbul/sbt001 PubMed

Geller V, Friger M, Sela BA, Levine J (2013) Elevated homocysteine level in siblings of patients with schizophrenia. Psychiatry Res 210(3):769–772. doi:10.1016/j.psychres.2013.08.016 PubMedCrossRef

Goff DC, Bottiglieri T, Arning E, Shih V, Freudenreich O, Evins AE, Henderson DC, Baer L, Coyle J (2004) Folate, homocysteine, and negative symptoms in schizophrenia. Am J Psychiatry 161(9):1705–1708. doi:10.1176/appi.ajp.161.9.1705 PubMedCrossRef

Gong J, Pinheiro JC, DeMets DL (2000) Estimating significance level and power comparisons for testing multiple endpoints in clinical trials. Control Clin Trials 21(4):313–329PubMedCrossRef

Hasnain M, Fredrickson SK, Vieweg WV, Pandurangi AK (2010) Metabolic syndrome associated with schizophrenia and atypical antipsychotics. Curr Diabetes Rep 10(3):209–216. doi:10.1007/s11892-010-0112-8 CrossRef

Hill M, Shannahan K, Jasinski S, Macklin EA, Raeke L, Roffman JL, Goff DC (2011) Folate supplementation in schizophrenia: a possible role for MTHFR genotype. Schizophr Res 127(1–3):41–45. doi:10.1016/j.schres.2010.12.006 PubMedCrossRef

Kale A, Naphade N, Sapkale S, Kamaraju M, Pillai A, Joshi S, Mahadik S (2010) Reduced folic acid, vitamin B12 and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: implications for altered one-carbon metabolism. Psychiatry Res 175(1–2):47–53. doi:10.1016/j.psychres.2009.01.013 PubMedCrossRef

Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13(2):261–276PubMedCrossRef

Keating E, Goncalves P, Campos I, Costa F, Martel F (2009) Folic acid uptake by the human syncytiotrophoblast: interference by pharmacotherapy, drugs of abuse and pathological conditions. Reprod Toxicol 28(4):511–520. doi:10.1016/j.reprotox.2009.07.001 PubMedCrossRef

Knight EM, James H, Edwards CH, Spurlock BG, Oyemade UJ, Johnson AA, West WL, Cole OJ, Westney LS, Westney OE et al (1994) Relationships of serum illicit drug concentrations during pregnancy to maternal nutritional status. J Nutr 124(6 Suppl):973S–980SPubMed

Kontis D, Theochari E, Fryssira H, Kleisas S, Sofocleous C, Andreopoulou A, Kalogerakou S, Gazi A, Boniatsi L, Chaidemenos A, Tsaltas E (2013) COMT and MTHFR polymorphisms interaction on cognition in schizophrenia: an exploratory study. Neurosci Lett 537:17–22. doi:10.1016/j.neulet.2013.01.012 PubMedCrossRef

Kumar A, John L, Maity S, Manchanda M, Sharma A, Saini N, Chakraborty K, Sengupta S (2011) Converging evidence of mitochondrial dysfunction in a yeast model of homocysteine metabolism imbalance. J Biol Chem 286(24):21779–21795. doi:10.1074/jbc.M111.228072 PubMedCentralPubMedCrossRef

Levine J, Stahl Z, Sela BA, Gavendo S, Ruderman V, Belmaker RH (2002) Elevated homocysteine levels in young male patients with schizophrenia. Am J Psychiatry 159(10):1790–1792PubMedCrossRef

Levine J, Stahl Z, Sela BA, Ruderman V, Shumaico O, Babushkin I, Osher Y, Bersudsky Y, Belmaker RH (2006) Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biol Psychiatry 60(3):265–269. doi:10.1016/j.biopsych.2005.10.009 PubMedCrossRef

Lipton SA, Kim WK, Choi YB, Kumar S, D’Emilia DM, Rayudu PV, Arnelle DR, Stamler JS (1997) Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A 94(11):5923–5928PubMedCentralPubMedCrossRef

Ma YY, Shek CC, Wong MC, Yip KC, Ng RM, Nguyen DG, Poon TK (2009) Homocysteine level in schizophrenia patients. Aust N Z J Psychiatry 43(8):760–765. doi:10.1080/00048670903001935 PubMedCrossRef

Mabrouk H, Douki W, Mechri A, Younes MK, Omezzine A, Bouslama A, Gaha L, Najjar MF (2011) Hyperhomocysteinemia and schizophrenia: case control study. L’Encéphale 37(4):308–313. doi:10.1016/j.encep.2010.12.004 PubMedCrossRef

Martins JM, Trinca A, Afonso A, Carreiras F, Falcao J, Nunes JS, do Vale S, da Costa JC (2001) Psychoneuroendocrine characteristics of common obesity clinical subtypes. Int J Obes Relat Metab Disord 25(1):24–32PubMedCrossRef

McEvoy J, Baillie RA, Zhu H, Buckley P, Keshavan MS, Nasrallah HA, Dougherty GG, Yao JK, Kaddurah-Daouk R (2013) Lipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychotics. PLoS ONE 8(7):e68717. doi:10.1371/journal.pone.0068717 PubMedCentralPubMedCrossRef

McGuffin P, Farmer A, Harvey I (1991) A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch Gen Psychiatry 48(8):764–770PubMedCrossRef

Misiak B, Frydecka D, Piotrowski P, Kiejna A (2013) The multidimensional nature of metabolic syndrome in schizophrenia: lessons from studies of one-carbon metabolism and DNA methylation. Epigenomics 5(3):317–329. doi:10.2217/epi.13.22 PubMedCrossRef

Mukherjee S, Schnur DB, Reddy R (1989) Family history of type 2 diabetes in schizophrenic patients. Lancet 1(8636):495PubMedCrossRef

Muntjewerff JW, Kahn RS, Blom HJ, den Heijer M (2006) Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Mol Psychiatry 11(2):143–149. doi:10.1038/sj.mp.4001746 PubMedCrossRef

Neeman G, Blanaru M, Bloch B, Kremer I, Ermilov M, Javitt DC, Heresco-Levy U (2005) Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type. Am J Psychiatry 162(9):1738–1740. doi:10.1176/appi.ajp.162.9.1738 PubMedCrossRef

Niemi-Pynttari JA, Sund R, Putkonen H, Vorma H, Wahlbeck K, Pirkola SP (2013) Substance-induced psychoses converting into schizophrenia: a register-based study of 18,478 Finnish inpatient cases. J Clin Psychiatry 74(1):e94–e99. doi:10.4088/JCP.12m07822 PubMedCrossRef

Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, Ueland M, Kvale G (1995) Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 274(19):1526–1533PubMedCrossRef

Peerbooms O, Rutten BP, Decoster J, van Os J, Kenis G, De Hert M, van Winkel R (2010) No association between MTHFR C677T or A1298C and age at onset of schizophrenia. Am J Med Genet B, Neuropsychiatr Genet 153B(7):1362–1363. doi:10.1002/ajmg.b.31114, author reply 1361

Petronijevic ND, Radonjic NV, Ivkovic MD, Marinkovic D, Piperski VD, Duricic BM, Paunovic VR (2008) Plasma homocysteine levels in young male patients in the exacerbation and remission phase of schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 32(8):1921–1926. doi:10.1016/j.pnpbp.2008.09.009 CrossRef

Phutane VH, Tek C, Chwastiak L, Ratliff JC, Ozyuksel B, Woods SW, Srihari VH (2011) Cardiovascular risk in a first-episode psychosis sample: a ‘critical period’ for prevention? Schizophr Res 127(1–3):257–261. doi:10.1016/j.schres.2010.12.008 PubMedCentralPubMedCrossRef

Pomerleau CS, Majchrzak MJ, Pomerleau OF (1989) Nicotine dependence and the Fagerstrom Tolerance Questionnaire: a brief review. J Subst Abuse 1(4):471–477PubMed

Roffman JL, Gollub RL, Calhoun VD, Wassink TH, Weiss AP, Ho BC, White T, Clark VP, Fries J, Andreasen NC, Goff DC, Manoach DS (2008a) MTHFR 677C -->T genotype disrupts prefrontal function in schizophrenia through an interaction with COMT 158Val --> Met. Proc Natl Acad Sci U S A 105(45):17573–17578. doi:10.1073/pnas.0803727105 PubMedCentralPubMedCrossRef

Roffman JL, Weiss AP, Deckersbach T, Freudenreich O, Henderson DC, Wong DH, Halsted CH, Goff DC (2008b) Interactive effects of COMT Val108/158Met and MTHFR C677T on executive function in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 147B(6):990–995. doi:10.1002/ajmg.b.30684 PubMed

Roffman JL, Weiss AP, Purcell S, Caffalette CA, Freudenreich O, Henderson DC, Bottiglieri T, Wong DH, Halsted CH, Goff DC (2008c) Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia. Biol Psychiatry 63(1):42–48. doi:10.1016/j.biopsych.2006.12.017 PubMedCrossRef

Roffman JL, Brohawn DG, Friedman JS, Dyckman KA, Thakkar KN, Agam Y, Vangel MG, Goff DC, Manoach DS (2011a) MTHFR 677C>T effects on anterior cingulate structure and function during response monitoring in schizophrenia: a preliminary study. Brain Imaging Behav 5(1):65–75. doi:10.1007/s11682-010-9111-2 PubMedCrossRef

Roffman JL, Nitenson AZ, Agam Y, Isom M, Friedman JS, Dyckman KA, Brohawn DG, Smoller JW, Goff DC, Manoach DS (2011b) A hypomethylating variant of MTHFR, 677C>T, blunts the neural response to errors in patients with schizophrenia and healthy individuals. PLoS ONE 6(9):e25253. doi:10.1371/journal.pone.0025253 PubMedCentralPubMedCrossRef

Roffman JL, Brohawn DG, Nitenson AZ, Macklin EA, Smoller JW, Goff DC (2013a) Genetic variation throughout the folate metabolic pathway influences negative symptom severity in schizophrenia. Schizophr Bull 39(2):330–338. doi:10.1093/schbul/sbr150 PubMedCentralPubMedCrossRef

Roffman JL, Lamberti JS, Achtyes E, Macklin EA, Galendez GC, Raeke LH, Silverstein NJ, Smoller JW, Hill M, Goff DC (2013b) Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia. JAMA Psychiatry 70(5):481–489. doi:10.1001/jamapsychiatry.2013.900 PubMedCrossRef

Ryan MC, Collins P, Thakore JH (2003) Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatr 160(2):284–289PubMedCrossRef

Saetre P, Vares M, Werge T, Andreassen OA, Arinami T, Ishiguro H, Nanko S, Tan EC, Han DH, Roffman JL, Muntjewerff JW, Jagodzinski PP, Kempisty B, Hauser J, Vilella E, Betcheva E, Nakamura Y, Regland B, Agartz I, Hall H, Terenius L, Jonsson EG (2011) Methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms and age of onset in schizophrenia: a combined analysis of independent samples. Am J Med Genet B Neuropsychiatr Genet 156(2):215–224. doi:10.1002/ajmg.b.31160 PubMed

Saetre P, Grove J, Borglum AD, Mors O, Werge T, Andreassen OA, Vares M, Agartz I, Terenius L, Jonsson EG (2012) Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and age at onset of schizophrenia: no consistent evidence for an association in the Nordic population. Am J Med Genet B Neuropsychiatr Genet 159B(8):981–986. doi:10.1002/ajmg.b.32104 PubMedCentralPubMed

Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH (2007) Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med 24(5):481–485. doi:10.1111/j.1464-5491.2007.02092.x PubMedCrossRef

Srisawat U, Reynolds GP, Zhang ZJ, Zhang XR, Arranz B, San L, Dalton CF (2013) Methylenetetrahydrofolate reductase (MTHFR) 677C/T polymorphism is associated with antipsychotic-induced weight gain in first-episode schizophrenia. Int J Neuropsychopharmacol 1–6. doi:10.1017/S1461145713001375

Ulrich CM, Robien K, Sparks R (2002) Pharmacogenetics and folate metabolism—a promising direction. Pharmacogenomics 3(3):299–313. doi:10.1517/14622416.3.3.299 PubMedCrossRef

van Winkel R, Moons T, Peerbooms O, Rutten B, Peuskens J, Claes S, van Os J, De Hert M (2010a) MTHFR genotype and differential evolution of metabolic parameters after initiation of a second generation antipsychotic: an observational study. Int Clin Psychopharmacol 25(5):270–276. doi:10.1097/YIC.0b013e32833bc60d PubMedCrossRef

van Winkel R, Rutten BP, Peerbooms O, Peuskens J, van Os J, De Hert M (2010b) MTHFR and risk of metabolic syndrome in patients with schizophrenia. Schizophr Res 121(1–3):193–198. doi:10.1016/j.schres.2010.05.030 PubMedCrossRef

Vares M, Saetre P, Deng H, Cai G, Liu X, Hansen T, Rasmussen HB, Werge T, Melle I, Djurovic S, Andreassen OA, Agartz I, Hall H, Terenius L, Jonsson EG (2010) Association between methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and age of onset in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 153B(2):610–618. doi:10.1002/ajmg.b.31030 PubMed

Wang J, Bai X, Chen Y, Zhao Y, Liu X (2012) Homocysteine induces apoptosis of rat hippocampal neurons by inhibiting 14-3-3epsilon expression and activating calcineurin. PLoS ONE 7(11):e48247. doi:10.1371/journal.pone.0048247 PubMedCentralPubMedCrossRef

Williams J, Farmer AE, Ackenheil M, Kaufmann CA, McGuffin P (1996) A multicentre inter-rater reliability study using the OPCRIT computerized diagnostic system. Psychol Med 26(4):775–783PubMedCrossRef

Wu X, Huang Z, Wu R, Zhong Z, Wei Q, Wang H, Diao F, Wang J, Zheng L, Zhao J, Zhang J (2013) The comparison of glycometabolism parameters and lipid profiles between drug-naive, first-episode schizophrenia patients and healthy controls. Schizophr Res 150(1):157–162. doi:10.1016/j.schres.2013.07.051 PubMedCrossRef

Wysokinski A, Kloszewska I (2013) Homocysteine levels in patients with schizophrenia on clozapine monotherapy. Neurochem Res 38(10):2056–2062. doi:10.1007/s11064-013-1113-1 PubMedCentralPubMedCrossRef

Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G (2002) Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 325(7374):1199PubMedCentralPubMedCrossRef

Zhang Y, Yan H, Tian L, Wang F, Lu T, Wang L, Yan J, Liu Q, Kang L, Ruan Y, Zhang D, Yue W (2013) Association of MTHFR C677T polymorphism with schizophrenia and its effect on episodic memory and gray matter density in patients. Behav Brain Res 243:146–152. doi:10.1016/j.bbr.2012.12.061 PubMedCentralPubMedCrossRef

Title: Elevated homocysteine level in first-episode schizophrenia patients—the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse
Authors: Blazej Misiak
Dorota Frydecka
Ryszard Slezak
Patryk Piotrowski
Andrzej Kiejna
Publication date: 01-09-2014
Publisher: Springer US
Published in: Metabolic Brain Disease / Issue 3/2014
Print ISSN: 0885-7490
Electronic ISSN: 1573-7365
DOI: https://doi.org/10.1007/s11011-014-9534-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Elevated homocysteine level in first-episode schizophrenia patients—the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2014

Role of iron in ischemia-induced neurodegeneration: mechanisms and insights

Effects of omega-3 on behavioral and biochemical parameters in rats submitted to chronic mild stress

Erratum to: Elevated homocysteine level in first-episode schizophrenia patients—the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse

Altered brain functional connectivity in hemodialysis patients with end-stage renal disease: a resting-state functionalMR imaging study

Erratum to: Protective effects of N-acetylcysteine on 3, 4-methylenedioxymethamphetamine-induced neurotoxicity in male Sprague–Dawley rats

Neuroprotective effects of guanosine administration on behavioral, brain activity, neurochemical and redox parameters in a rat model of chronic hepatic encephalopathy